All In Biotech

Drug Trial Radar · NCT05350969

Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction

Phase 2, Multicenter, Randomized, Parallel, 3-arm, Placebo-controlled Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction (≤ 45%) After Myocardial Infarction

Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 294 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

294

Actual

Start

Jul 11, 2022

Primary completion

Sep 26, 2024

Study completion Mar 17, 2025

Sponsor

Lead sponsor
Cardior Pharmaceuticals GmbHIndustry
Sponsor type
Industry
First posted
Apr 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multicenter, randomized, parallel, 3-arm, placebo-controlled study to assess efficacy and safety of CDR132L in patients with reduced Left Ventricular Ejection Fraction (LVEF) (≤ 45%) after myocardial infarction (MI). This study consists of a screening period (to occur at least 3 days after MI diagnosis), a 6-month double-blind period, and a 6-month extension period with the End of Study (EOS) Visit at Day 360/Month 12. Two dosages of CDR132L will be tested against placebo on their effects on patients, who just had a heart attack in addition to standard care. The aim of the study is to show that CDR132L is safe and effective to improve heart failure in such patients.

Conditions

  • Myocardial Infarction, Acute
  • Heart Failure, Left Sided

Interventions

  • CDR132LDrug

    CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.

  • Placebo to CDR132LDrug

    Placebo to CDR132L

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in LVESVI (Left Ventricular End-systolic Volume Index) at Month 6Time frame: Baseline (Day 1), Month 6

Locations

49 sites in 8 countries. Site status is shown where the registry gives one.

  • Institut klinicke a experimentalni mediciny

    Prague, Czechia

  • Všeobecná fakultní nemocnice v Praze

    Prague, Czechia

  • St. Marien-Krankenhaus Ahaus

    Ahaus, Germany

  • Herzzentrum Dresden Universitätsklinik

    Dresden, Germany

  • Helios Klinikum Erfurt

    Erfurt, Germany

  • Universitätsmedizin Göttingen

    Göttingen, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Universitätsklinikum Schleswig-Holstein

    Kiel, Germany

  • Klinikum Ludwigshafen

    Ludwigshafen, Germany

  • Universitätsklinikum Würzburg

    Würzburg, Germany

  • "Alexandra" General Hospital of Athens

    Athens, Greece

  • "Attikon" General University Hospital

    Athens, Greece

  • General University Hospital of Patras "Panagia i Voitheia"

    Pátrai, Greece

  • Semmelweis University

    Budapest, Hungary

  • Jeroen Bosch Ziekenhuis (JBZ) (Hieronymus Bosch Hospital) - locatie Den Bosch

    's-Hertogenbosch, Netherlands

  • Deventer Ziekenhuis

    Deventer, Netherlands

  • Slingeland Ziekenhuis

    Doetinchem, Netherlands

  • Gelderse Vallei Ziekenhuis

    Ede, Netherlands

  • Medisch Centrum Leeuwarden

    Leeuwarden, Netherlands

  • St. Jansdal Ziekenhuis

    Lelystad, Netherlands

  • Erasmus University Medical Center

    Rotterdam, Netherlands

  • Ikazia Ziekenhuis

    Rotterdam, Netherlands

  • D & A Research B.V.

    Sneek, Netherlands

  • Gelre Ziekenhuizen

    Zutphen, Netherlands

  • Polsko Amerykanskie Kliniki Serca

    Kędzierzyn-Koźle, Poland

  • Specjalistyczna Poradnia Kardiologiczna i Nadcisnienia Tetniczego

    Kielce, Poland

  • Krakowski Szpital Specjalistyczny im. Jana Pawla II

    Krakow, Poland

  • Gabinet Internistyczno-Kardiologiczny Jacek Nowak

    Libiąż, Poland

  • NZOZ SALUS JZ Peruga

    Lodz, Poland

  • One wojskowy Szpital Kliniczny w Lublinie

    Lublin, Poland

  • Medicome Sp. z o.o.

    Oświęcim, Poland

  • Wojewódzki Szpital im. Sw. Ojca Pio w Przemyslu

    Przemyśl, Poland

  • NZOZ Pro-Cordis Sopockie Centrum Bad. Kardiolog

    Sopot, Poland

  • Wojewodzki Szpital Zespolony

    Torun, Poland

  • Spec.Szpital im.dr Sokolowskiego

    Wałbrzych, Poland

  • Investigational Site

    Wroclaw, Poland

  • Hospital Universitari Germans Trias i Pujol

    Badalona, Spain

  • Hospital de la Santa Creu I Sant Pau

    Barcelona, Spain

  • Hospital Universitario San Cecilio

    Granada, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.